Business Model

Secarna strives to become the partner of choice for antisense oligonucleotides (ASO) drug discovery and development programs.

Our flexible partnership model is set to accommodate the best mix of in-house and partner collaborations. Three typical structures are found in our partnership portfolio:

Program Licenses: Single asset deals to out-license high-value, assets for further development and commercialization by partners

Discovery & Research Alliances: Platform deals for multiple-asset discovery and development collaborations leveraging Secarna’s entire toolbox to generate partnered and co-owned ASO pipelines

In-house development: High value programs progressed to and through early-stage clinical studies followed by the potential out-licensing of these candidates to partners

Current Partnerships

Currently, we have a total of six disclosed discovery and development partnerships and further yet undisclosed partnerships.

Additionally, we are collaborating with leading companies that support us in various fields.

If you are interested in collaborating with Secarna, please contact us at This email address is being protected from spambots. You need JavaScript enabled to view it..